CoChat

Rimonabant for overweight or obesity

Open access
Curioni, Cintia, André, Charles · 2006 · Cochrane Database of Systematic Reviews
Cited by 144

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Worldwide, the prevalence of obesity and overweight in industrialized countries and in a substantial number of developing countries is increasing at an alarming rate. Rimonabant is a selective cannabinoid-1 receptor antagonist that has been investigated for its efficacy in reducing body weight and associated risk factors in obese people. Phase III trials are now under way to test the use of rimonabant for long-term weight-loss. Given the prevalence of overweight and obesity, it is important to establish the efficacy and safety of rimonabant. OBJECTIVES: To assess the effects of rimonabant in overweight and obese people. SEARCH STRATEGY: MEDLINE, EMBASE, The Cochrane Library, LILACS, databases of ongoing trials and reference lists were used to identify relevant trials. The last search was conducted in June 2006. SELECTION CRITERIA: Randomised controlled trials comparing rimonabant with placebo or other weight loss interventions in overweight or obese adults. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed all potentially relevant citations for inclusion and methodological quality. The primary outcome measures were weight loss change, morbidity and adverse effects occurrence. MAIN RESULTS: Four studies evaluating rimonabant 20 mg versus rimonabant 5 mg versus placebo in addition to a hypocaloric diet lasting at least one year were included. Compared with placebo, rimonabant 20 mg produced a 4.9 kg greater reduction in body weight in trials with one-year results. Improvements in waist circumference, high-density lipoprotein cholesterol, triglyceride levels and systolic and diastolic blood pressure were also seen. However, the results with rimonabant 5 mg demonstrated a weight reduction which was only 1.3 kg greater when compared with placebo. No clinically relevant effects on plasma lipids and blood pressure were found. Rimonabant 20 mg caused significant more adverse effects both of general and serious nature, especially of nervous system, psychiatric or gastro-intestinal origin. Attrition rates were approximately 40% at the end of one year. AUTHORS' CONCLUSIONS: The use of rimonabant after one year produces modest weight loss of approximately 5%. Even modest amounts of weight loss may be potentially beneficial. The observed results should be interpreted with some caution, though, since the evaluated studies presented some deficiencies in methodological quality. Studies with longer follow-ups after the end of treatment and of more rigorous quality should be done before definitive recommendations can be made regarding the role of this new medication in the management of overweight or obese patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd006162.pub2

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 45

  1. Gaal, 2005, Effect of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, The Lancet, 365, 1389, 10.1016/S0140-6736(05)66374-X · DOI · Paper page
  2. Pi-Sunyer, 2006, Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients, JAMA, 295, 761, 10.1001/jama.295.7.761 · DOI · Paper page
  3. Jesen, 2004, The selective cb1-receptor antagonist rimonabant reduces body weight and waist circumference in obese subjects, International Journal of Obesity, 28 (Suppl. 1), S27
  4. Bergstrom, 2001, Overweight as an avoidable cause of cancer in Europe, International Journal of Cancer, 1, 421, 10.1002/1097-0215(200002)9999:9999<::AID-IJC1053>3.0.CO;2-T · DOI · Paper page
  5. Björntorp, 1984, Hazards in subgroups of human obesity, European Journal of Clinical Investigation, 14, 239, 10.1111/j.1365-2362.1984.tb01174.x · DOI
  6. Björntorp, 1985, Obesity and the risk of cardiovascular disease, Annals of Clinical Research, 17, 3
  7. Bonner, 2005, Structure of a cannabinoid receptor and functional antagonist, Annals of Pharmacotherapy, 39, 684
  8. Boyd, 2005, Rimonabant - a selective CB1 antagonist, The Annals of Pharmacotherapy, 39, 684, 10.1345/aph.1E499 · DOI
  9. Chu, 1991, The relationship between body mass and breast cancer among women enrolled in the Cancer and Steroid Hormone Study, Journal of Clinical Epidemiology, 44, 1197, 10.1016/0895-4356(91)90152-Y · DOI
  10. Chua, 1994, Obstructive sleep apnea. Treatment improves quality of life and may prevent death, Postgraduate Medicine, 95, 123, 10.1080/00325481.1994.11945797 · DOI
  11. Cicuttini, 1996, The association of obesity with osteoarthritis of the hand and knee in women: a twin study, Journal of Rheumatology, 23, 1221
  12. Cohen, 1960, A coefficient of agreement for nominal scales, Educational and Psychological Measurement, 20, 37, 10.1177/001316446002000104 · DOI · Paper page
  13. Colombo, 1998, Appetite suppression and weight loss after the cannabinoid antagonist SR 141716, Life Sciences, 63, PL113, 10.1016/S0024-3205(98)00322-1 · DOI · Paper page
  14. Cox, 2005, Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors, Drugs of Today, 41, 499, 10.1358/dot.2005.41.8.893709 · doi:10.1358/dot.2005.41.8.893709
  15. Curioni, 2005, Long-term weight loss after diet and exercise - a systematic review, International Journal of Obesity and related metabolic disorders, 29, 1168, 10.1038/sj.ijo.0803015 · DOI · Paper page
  16. Marzo, 2005, Endocannabinoid control of food intake and energy balance, Nature Neuroscience, 8, 585, 10.1038/nn1457 · DOI · Paper page
  17. Donahue, 1987, Central obesity and coronary heart disease in men, Lancet, 1, 821, 10.1016/S0140-6736(87)91605-9 · DOI · Paper page
  18. Ducimetiere, 1986, The pattern of subcutaneous fat distribution in middle-aged men and risk of coronary heart disease: The Paris Prospective Study, International Journal of Obesity, 10, 229
  19. Dyer, 1989, The INTERSALT study: relations of body mass index to blood pressure. INTERSALT Co-operative Research Group, Journal of Human Hypertension, 3, 299
  20. Egger, 1997, Bias in meta-analysis detected by a simple graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  21. Gelfand, 2006, Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors, Journal of the American College of cardiology, 47, 1919-26, 10.1016/j.jacc.2005.12.067 · DOI
  22. Greenway, 1996, Obesity surgery, Endocrinology and Metabolism Clinics of North America, 25, 1005, 10.1016/S0889-8529(05)70367-4 · DOI
  23. Halford, 2006, Obesity drugs in clinical development, Current Opinion in Investigational Drugs, 7, 312
  24. Hart, 1993, The relationship of obesity, fat distribution, and osteoarthritis in women in the general population: the Chingford Study, The Journal of Rheumatololy, 20, 331
  25. Hey, 2005, Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation, The Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005353 · doi:10.1002/14651858.cd005353
  26. Higgins, 2003, Measuring inconsistency in meta-analysis, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  27. Higgins, 2005, Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] In: The Cochrane Library
  28. Kissebah, 1985, Endrocrine characteristics in regional obesities:role of sex steroids, 115
  29. Lapidus, 1984, Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow-up of participants in the population study of women in Gothenburg, Sweden, British Medical Journal (Clinical Research Ed.), 289, 1257, 10.1136/bmj.289.6454.1257 · DOI · Paper page
  30. Larsson, 1984, Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913, British Medical Journal (Clinical Research Ed.), 288, 1401, 10.1136/bmj.288.6428.1401 · DOI · Paper page
  31. Luque, 1999, Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity, Annals of Pharmacotherapy, 33, 968, 10.1345/aph.18319 · DOI · Paper page
  32. McNeely, 1998, Orlistat, Drugs, 52, 241, 10.2165/00003495-199856020-00007 · DOI
  33. Medalie, 1974, Diabetes mellitus among 10,000 adult men. I. 5-year incidence and associated variables, Israel Journal of Medical Sciences, 10, 681
  34. Lung, 1998, Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report (Clinical Gdlns), Obesity Research, 6, 51S
  35. National Institutes of Health Consensus Development Conference Statement (NIHCD), 1985, Health implications of obesity, Annals of Internal Medicine, 103, 1073, 10.7326/0003-4819-103-6-1073 · DOI · Paper page
  36. Ohlson, 1985, The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913, Diabetes, 34, 1055, 10.2337/diab.34.10.1055 · DOI · Paper page
  37. Rinaldi-Carmona, 2004, SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization, The Journal of Pharmacology and Experimental Therapeutics, 310, 905, 10.1124/jpet.104.067884 · DOI
  38. Rowland, 2001, Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats, Psychopharmacology, 159, 111, 10.1007/s002130100910 · DOI
  39. Schottenfeld, 1996, Cancer Epidemiology and Prevention
  40. Simiand, 1998, SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset, Behavioural Pharmacology, 9, 179
  41. Stokes III, 1985, The independent contributions of various indices of obesity to the 22-year incidence of coronary heart disease: The Framingham Heart Study
  42. Tonstad, 2006, Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors, Nutrition, Metabolism & Cardiovascular Diseases, 16, 156, 10.1016/j.numecd.2005.10.011 · DOI
  43. Vickers, 2005, Cannabinoids and the regulation of ingestive behaviour, Current Drug Targets, 6, 215, 10.2174/1389450053174514 · DOI · Paper page
  44. Walker, 1996, Body size and fat distribution as predictors of stroke among US men, American Journal of Epidemiology, 144, 1143, 10.1093/oxfordjournals.aje.a008892 · DOI · Paper page
  45. Werner, 2003, Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats, Brain Research, 28, 290, 10.1016/S0006-8993(02)04274-9 · DOI

Cited by

See all 144

Metadata

Authors
Curioni, C., & André, C.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2006-10-18
Volume
2010
Issue
1
Pages
CD006162-CD006162
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1508039321
Cited by
144
References
7
FWCI
14.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.